PARP1 and neoplasm: PARP inhibition has a potential therapeutic role as monotherapy in tumours carrying constitutive mutations in DDR genes, as well as in combination therapies for its ability to enhance the activity of anticancer drugs with genotoxic action, including DNA alkylating agents, topoisomerase II inhibitors and ionising radiation (IR) (Jorgensen 2009; Kelley et al. 2014; Lord and Ashworth 2017), since targeting similar molecular functions results in cell death.